Victoria Socha

DocwireNews

The mortality risk from COVID-19 is increased in kidney transplant recipients. A. O. G&eacute;rard and colleagues conducted a study to examine the association between maintenance immunosuppressive drugs and 60-day mortality in kidney transplant recipients with COVID-19.Results of the study were reported during an oral presentation at the 2022 American Transplant Congress. The presentation was titled Association Between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients.Data from all kidney transplant recipients with COVID-19 in the French Solid Organ Transplant COVID-19 registry from February 28, 2020, to December 30, 2020, were retrieved. Patients with missing data on i<a href="https://www.docwirenews.com/nephtimes/immunosuppression-and-quality-of-life-a-qualitative-study/">mmunosuppressive</a> therapy were excluded (n=116). Logistic regression was used to assess associations between immunosuppressive drugs and death within 60 days of COVID-19 symptom onset, with all baseline characteristics considered to influence outcome or immunosuppressive regimen. False positive rate was controlled for using Benjamini-Hochberg correction; 40 multiple imputations were performed. An adjusted P value of &lt;.05 was considered statistically significant.The cohort included 1451 kidney transplant recipients with COVID-19. Median age was 58 years, and 66.4% (n=963) were female. The most common comorbidities were hypertension (81.9%, n=1188), diabetes (34.5%, n=501), and cardiovascular disease (29.5%, n=428). Median time since transplant was 71 months. Maintenance immunosuppression regimen included calcineurin inhibitors (89.2%, n=1295), antimetabolites (83%, n=1205), corticosteroids (75.4%, n=1094), mammalian target of rapamycin inhibitors (9.9%, n=144), and belatacept (4.0%, n=58).Of the 1451 patients, 13.9% (n=201) died within 60 days of COVID-19 symptom onset. Older age and baseline creatininemia were associated with mortality (odds ratio [OR], 1.09; 95% CI, 1.07-1.11 and OR, 1.01; 95% CI, 1.005-1.009, respectively; P&lt;.001). There was an association between corticosteroid-free regimens and a significantly lower risk of death (OR, 0.48; 95% CI, 0.31-0.76; P=.011). There were no significant P values with all other variables.&ldquo;Corticosteroid-free regimens were associated with a lower risk of death in kidney transplant recipients with COVID-19,&rdquo; the authors said. &ldquo;While a short course of high-dose corticosteroids is beneficial in severely ill COVID-19 patients, prolonged maintenance corticosteroids expose to chronic immune disorders that may predispose kidney transplant recipients&nbsp; to severe forms of COVID-19.&rdquo;Source: G&eacute;rard AO., Barbosa S, Anglicheau D, et al. Association between maintenance immunosuppressive regimens and COVID-19 mortality in kidney transplant recipients. Abstract of an oral presentation at the 2022 American Transplant Congress (Abstract 9026), Boston, Massachusetts, June 6, 2022.

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Latest News

Immunosuppression and Mortality in KT Recipients With COVID-19

American Transplant Congress 2022

The mortality risk from COVID-19 is increased in kidney transplant recipients. A. O. Gérard and colleagues conducted a study to examine the association between maintenance ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe